AR102594A1 - ANTICUERPOS ANTI-IL-1b Y MÉTODOS DE USO - Google Patents
ANTICUERPOS ANTI-IL-1b Y MÉTODOS DE USOInfo
- Publication number
- AR102594A1 AR102594A1 ARP150103647A ARP150103647A AR102594A1 AR 102594 A1 AR102594 A1 AR 102594A1 AR P150103647 A ARP150103647 A AR P150103647A AR P150103647 A ARP150103647 A AR P150103647A AR 102594 A1 AR102594 A1 AR 102594A1
- Authority
- AR
- Argentina
- Prior art keywords
- amino acid
- hvr
- seq
- acid sequence
- acid residue
- Prior art date
Links
- 150000001413 amino acids Chemical group 0.000 abstract 6
- 125000000539 amino acid group Chemical group 0.000 abstract 4
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 abstract 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
- 208000014245 Ocular vascular disease Diseases 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
- 235000004279 alanine Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 229960000310 isoleucine Drugs 0.000 abstract 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 1
- 239000004474 valine Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14192523 | 2014-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR102594A1 true AR102594A1 (es) | 2017-03-08 |
Family
ID=51868114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150103647A AR102594A1 (es) | 2014-11-10 | 2015-11-09 | ANTICUERPOS ANTI-IL-1b Y MÉTODOS DE USO |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10344085B2 (enExample) |
| EP (1) | EP3218402A1 (enExample) |
| JP (1) | JP6787888B2 (enExample) |
| KR (1) | KR20170081253A (enExample) |
| CN (1) | CN107074942A (enExample) |
| AR (1) | AR102594A1 (enExample) |
| AU (1) | AU2015345320A1 (enExample) |
| BR (1) | BR112017009817A2 (enExample) |
| CA (1) | CA2963719A1 (enExample) |
| IL (1) | IL251165A0 (enExample) |
| MX (1) | MX2017005987A (enExample) |
| RU (1) | RU2017120358A (enExample) |
| SG (1) | SG11201702550WA (enExample) |
| TW (1) | TW201632552A (enExample) |
| WO (1) | WO2016075034A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100256340A1 (en) | 2009-04-07 | 2010-10-07 | Ulrich Brinkmann | Trivalent, bispecific antibodies |
| JP6946184B2 (ja) | 2014-11-10 | 2021-10-06 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 抗ｐｄｇｆ−ｂ抗体及び使用法 |
| SG11201703428SA (en) | 2014-11-10 | 2017-05-30 | Hoffmann La Roche | Bispecific antibodies and methods of use in ophthalmology |
| EP3218402A1 (en) | 2014-11-10 | 2017-09-20 | F. Hoffmann-La Roche AG | Anti-il-1beta antibodies and methods of use |
| CN107001456A (zh) | 2014-11-10 | 2017-08-01 | 豪夫迈·罗氏有限公司 | 抗ang2 抗体及使用方法 |
| CN107001482B (zh) | 2014-12-03 | 2021-06-15 | 豪夫迈·罗氏有限公司 | 多特异性抗体 |
| AR111761A1 (es) * | 2017-05-16 | 2019-08-14 | Cj Healthcare Corp | Un método para purificar un anticuerpo o un fragmento de anticuerpo de este usando cromatografía de afinidad |
| WO2018212556A1 (en) * | 2017-05-16 | 2018-11-22 | Cj Healthcare Corporation | A method for purifying an antibody or an antibody fragment thereof using affinity chromatography |
| CN118994394A (zh) | 2017-06-12 | 2024-11-22 | 蓝鳍生物医药公司 | 抗-il1rap抗体和抗体药物缀合物 |
| IL318916A (en) * | 2018-01-26 | 2025-04-01 | Genzyme Corp | FC variants with improved binding to FCRN and extended half-life |
| CN110818793A (zh) * | 2018-08-14 | 2020-02-21 | 中山康方生物医药有限公司 | 抗IL-1β的抗体、其药物组合物及其用途 |
| CR20210332A (es) * | 2018-12-21 | 2021-09-09 | Hoffmann La Roche | Anticuerpo que se une a vegf y a il-1beta y métodos de utilización |
| CN115028723B (zh) * | 2019-03-07 | 2023-08-29 | 瑞阳(苏州)生物科技有限公司 | 人IL-1β蛋白结合分子及其编码基因和应用 |
| JP7387196B2 (ja) * | 2019-06-11 | 2023-11-28 | バイオアトラ インコーポレイテッド | 条件付きで活性な抗ｅｐｃａｍ抗体、抗体フラグメント、それらのイムノコンジュゲート、及びそれらの使用 |
| CN114524875B (zh) * | 2021-11-11 | 2023-07-25 | 江苏莱森生物科技研究院有限公司 | 偶联IL-1β单克隆抗体的纳米硅球及应用 |
| CN117126278B (zh) * | 2023-10-26 | 2024-01-05 | 中国科学院苏州纳米技术与纳米仿生研究所 | 一种单克隆抗体及其应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4935343A (en) * | 1986-08-08 | 1990-06-19 | Syntex (U.S.A.) Inc. | Monoclonal antibodies for interleukin-1β |
| JP2005518802A (ja) * | 2002-02-28 | 2005-06-30 | イーライ・リリー・アンド・カンパニー | 抗インターロイキン−１ベータ類縁体 |
| EP1600459A3 (en) | 2002-06-28 | 2005-12-07 | Domantis Limited | Ligand |
| ES2567198T3 (es) * | 2003-01-24 | 2016-04-20 | Applied Molecular Evolution, Inc. | Antagonistas de la IL-1 beta humana |
| US20050226863A1 (en) * | 2003-11-20 | 2005-10-13 | Massachusetts Institute Of Technology | Single-domain antibodies and uses thereof |
| US20050282233A1 (en) | 2004-03-05 | 2005-12-22 | Ludwig Institute For Cancer Research | Multivalent antibody materials and methods for VEGF/PDGF family of growth factors |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| AU2010208637A1 (en) * | 2009-01-29 | 2011-08-04 | Abbvie Inc. | IL-1 binding proteins |
| KR20120104542A (ko) * | 2009-10-15 | 2012-09-21 | 아보트 러보러터리즈 | Ｉｌ?１ 결합 단백질 |
| AR080794A1 (es) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
| CN104474546A (zh) * | 2010-08-13 | 2015-04-01 | 弗·哈夫曼-拉罗切有限公司 | 用于疾病治疗的针对IL-1β和IL-18的抗体 |
| NZ607510A (en) * | 2010-09-10 | 2014-10-31 | Apexigen Inc | Anti-il-1 beta antibodies and methods of use |
| JP6009455B2 (ja) * | 2010-12-21 | 2016-10-19 | アッヴィ・インコーポレイテッド | Ｉｌ−１アルファおよびベータ二重特異的二重可変ドメイン免疫グロブリンおよびその使用 |
| EP2726088B1 (en) | 2011-06-29 | 2019-01-02 | Amgen Inc. | Predictive biomarker of survival in the treatment of renal cell carcinoma |
| AU2013283296A1 (en) | 2012-06-28 | 2015-02-05 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to platelet-derived growth factor |
| NZ702201A (en) | 2012-07-13 | 2018-01-26 | Roche Glycart Ag | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
| MX2015003894A (es) | 2012-09-28 | 2015-07-17 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden aglutinantes duales de angiopoyetina-2 / dll4 agentes anti-vegf. |
| CA2883807A1 (en) | 2012-09-28 | 2014-04-03 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf-r agents |
| CA2890471C (en) | 2012-11-08 | 2021-07-27 | Clearside Biomedical, Inc. | Methods and devices for the treatment of ocular diseases in human subjects |
| AU2013343099A1 (en) | 2012-11-09 | 2015-05-14 | Pfizer Inc. | Platelet-derived growth factor B specific antibodies and compositions and uses thereof |
| JO3405B1 (ar) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
| EP2970459A2 (en) * | 2013-03-15 | 2016-01-20 | AbbVie Inc. | Dual specific binding proteins directed against il-1beta and il-17 |
| SG10201800492PA (en) * | 2013-04-29 | 2018-03-28 | Hoffmann La Roche | Human fcrn-binding modified antibodies and methods of use |
| JP6345787B2 (ja) | 2013-12-20 | 2018-06-20 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 抗ａｎｇ２抗体とｃｄ４０アゴニストとの併用療法 |
| RU2727639C2 (ru) | 2014-01-15 | 2020-07-22 | Ф.Хоффманн-Ля Рош Аг | Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а |
| JP6946184B2 (ja) | 2014-11-10 | 2021-10-06 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 抗ｐｄｇｆ−ｂ抗体及び使用法 |
| CN107001456A (zh) | 2014-11-10 | 2017-08-01 | 豪夫迈·罗氏有限公司 | 抗ang2 抗体及使用方法 |
| SG11201703428SA (en) | 2014-11-10 | 2017-05-30 | Hoffmann La Roche | Bispecific antibodies and methods of use in ophthalmology |
| EP3218402A1 (en) | 2014-11-10 | 2017-09-20 | F. Hoffmann-La Roche AG | Anti-il-1beta antibodies and methods of use |
| WO2016209972A1 (en) | 2015-06-26 | 2016-12-29 | Amgen Inc. | Biomarker of survival in the treatment of renal cell carcinoma with a vegfr inhibitor and an ang2 inhibitor |
| EP3630822A1 (en) | 2017-06-02 | 2020-04-08 | Boehringer Ingelheim International GmbH | Anti-cancer combination therapy |
-
2015
- 2015-11-06 EP EP15790945.8A patent/EP3218402A1/en not_active Withdrawn
- 2015-11-06 BR BR112017009817A patent/BR112017009817A2/pt not_active Application Discontinuation
- 2015-11-06 SG SG11201702550WA patent/SG11201702550WA/en unknown
- 2015-11-06 AU AU2015345320A patent/AU2015345320A1/en not_active Abandoned
- 2015-11-06 WO PCT/EP2015/075875 patent/WO2016075034A1/en not_active Ceased
- 2015-11-06 KR KR1020177015590A patent/KR20170081253A/ko not_active Withdrawn
- 2015-11-06 RU RU2017120358A patent/RU2017120358A/ru not_active Application Discontinuation
- 2015-11-06 JP JP2017525023A patent/JP6787888B2/ja not_active Expired - Fee Related
- 2015-11-06 CN CN201580060880.4A patent/CN107074942A/zh active Pending
- 2015-11-06 CA CA2963719A patent/CA2963719A1/en not_active Abandoned
- 2015-11-06 MX MX2017005987A patent/MX2017005987A/es unknown
- 2015-11-09 AR ARP150103647A patent/AR102594A1/es unknown
- 2015-11-09 TW TW104136907A patent/TW201632552A/zh unknown
-
2017
- 2017-03-14 IL IL251165A patent/IL251165A0/en unknown
- 2017-05-09 US US15/590,161 patent/US10344085B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP3218402A1 (en) | 2017-09-20 |
| US20170247447A1 (en) | 2017-08-31 |
| AU2015345320A1 (en) | 2017-04-06 |
| RU2017120358A3 (enExample) | 2019-05-29 |
| RU2017120358A (ru) | 2018-12-13 |
| US10344085B2 (en) | 2019-07-09 |
| KR20170081253A (ko) | 2017-07-11 |
| BR112017009817A2 (pt) | 2018-02-14 |
| MX2017005987A (es) | 2017-06-29 |
| CN107074942A (zh) | 2017-08-18 |
| IL251165A0 (en) | 2017-04-30 |
| WO2016075034A1 (en) | 2016-05-19 |
| JP2017534646A (ja) | 2017-11-24 |
| SG11201702550WA (en) | 2017-04-27 |
| TW201632552A (zh) | 2016-09-16 |
| CA2963719A1 (en) | 2016-05-19 |
| JP6787888B2 (ja) | 2020-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR102594A1 (es) | ANTICUERPOS ANTI-IL-1b Y MÉTODOS DE USO | |
| AR102592A1 (es) | Anticuerpos biespecíficos y métodos de uso en oftalmología | |
| AR102593A1 (es) | Anticuerpos anti-pdgf-b y métodos de uso | |
| PE20161571A1 (es) | Anticuerpos anti-ox40 y metodos de uso | |
| JP2020500538A5 (enExample) | ||
| ES2685424T3 (es) | Anticuerpos anti-Jagged1 y procedimientos de uso | |
| AR096687A1 (es) | Anticuerpos anti-fcrh5 | |
| IL257281A (en) | Anti-pd-1 antibodies and methods of using them | |
| PE20170935A1 (es) | Anticuerpos anti-her2 e inmunoconjugados | |
| AR106991A1 (es) | Anticuerpos neutralizantes del virus de inmunodeficiencia humana | |
| AR086044A1 (es) | Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos | |
| AR091701A1 (es) | Anticuerpos anti-cd22 e inmunoconjugados | |
| HRP20200767T1 (hr) | Humanizirana anti-humana cd19 protutijela i postupci uporabe | |
| PE20181270A1 (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano | |
| PE20201186A1 (es) | Anticuerpos antitau y metodos de uso | |
| PE20170953A1 (es) | ANTICUERPOS ANTI-CD79b Y METODOS DE USO | |
| PE20150614A1 (es) | Inmunoconjugados que comprenden un anticuerpo anti-cd79b ligado a un derivado de nemorrubicina | |
| HRP20240719T1 (hr) | Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba | |
| PE20220487A1 (es) | Anticuerpos anti-ms4a4a y metodos de uso de los mismos | |
| PE20161376A1 (es) | Anticuerpos de hemaglutinina contra el virus de la influenza b y metodos de uso | |
| PE20161245A1 (es) | Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos | |
| JP2018507220A5 (enExample) | ||
| PE20141562A1 (es) | Anticuerpos anti-htra1 y metodos de uso | |
| PE20190733A1 (es) | Anticuerpos contra el virus del dengue, polipeptidos que contienen regiones fc variantes, y metodos de uso | |
| AR103713A1 (es) | Anticuerpos contra tau y sus usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |